Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Analyst Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PVLA Stock 12 Month Forecast
Average Price Target
$232.50
▲(93.70% Upside)
| Highest Price Target$270.00 | Average Price Target$232.50 | Lowest Price Target$209.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$76.43→$227
Buy
89.12%
Upside
Reiterated
04/02/26
LifeSci Capital
$90→$222
Buy
84.95%
Upside
Reiterated
04/01/26
H.C. Wainwright
$270
Buy
124.94%
Upside
Reiterated
04/01/26
Mizuho Securities
$250
Buy
108.28%
Upside
Reiterated
04/01/26
BTIG
$215
Buy
79.12%
Upside
Reiterated
04/01/26
TD Cowen
$267
Buy
122.44%
Upside
Reiterated
03/31/26
Oppenheimer
$200→$210
Buy
74.96%
Upside
Reiterated
03/31/26
Chardan Capital
$220→$240
Buy
99.95%
Upside
Reiterated
03/31/26
Craig-Hallum
―
Buy
―
Reiterated
03/19/26
Clear Street
$200→$220
Buy
83.29%
Upside
Reiterated
03/02/26
Truist Financial
$190→$210
Buy
74.96%
Upside
Reiterated
02/25/26
Stifel Nicolaus
$180→$250
Buy
108.28%
Upside
Reiterated
02/24/26
JonesTrading
$143→$209
Buy
74.12%
Upside
Reiterated
02/24/26
Cantor Fitzgerald
$200→$210
Buy
74.96%
Upside
Reiterated
12/15/25
Lucid Capital
$122→$212
Buy
76.62%
Upside
Reiterated
12/15/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$76.43→$227
Buy
89.12%
Upside
Reiterated
04/02/26
LifeSci Capital
$90→$222
Buy
84.95%
Upside
Reiterated
04/01/26
H.C. Wainwright
$270
Buy
124.94%
Upside
Reiterated
04/01/26
Mizuho Securities
$250
Buy
108.28%
Upside
Reiterated
04/01/26
BTIG
$215
Buy
79.12%
Upside
Reiterated
04/01/26
TD Cowen
$267
Buy
122.44%
Upside
Reiterated
03/31/26
Oppenheimer
$200→$210
Buy
74.96%
Upside
Reiterated
03/31/26
Chardan Capital
$220→$240
Buy
99.95%
Upside
Reiterated
03/31/26
Craig-Hallum
―
Buy
―
Reiterated
03/19/26
Clear Street
$200→$220
Buy
83.29%
Upside
Reiterated
03/02/26
Truist Financial
$190→$210
Buy
74.96%
Upside
Reiterated
02/25/26
Stifel Nicolaus
$180→$250
Buy
108.28%
Upside
Reiterated
02/24/26
JonesTrading
$143→$209
Buy
74.12%
Upside
Reiterated
02/24/26
Cantor Fitzgerald
$200→$210
Buy
74.96%
Upside
Reiterated
12/15/25
Lucid Capital
$122→$212
Buy
76.62%
Upside
Reiterated
12/15/25
Best Analysts Covering Palvella Therapeutics
3 Months
xxx
Success Rate
10/11 ratings generated profit
Average Return
+74.17%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +74.17% per trade.
1 Year
Success Rate
11/11 ratings generated profit
Average Return
+323.05%
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +323.05% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+355.36%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +355.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PVLA Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
24
28
38
33
33
Buy
16
16
7
5
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
44
45
38
35
Each month's total comprises the sum of three months' worth of ratings.
PVLA Financial Forecast
PVLA Stock Forecast FAQ
What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 232.50.
What is PVLA’s upside potential, based on the analysts’ average price target?
Palvella Therapeutics has 93.70% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PVLA a Buy, Sell or Hold?
Palvella Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
What is Palvella Therapeutics’s price target?
The average price target for Palvella Therapeutics is 232.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $270.00 ,the lowest forecast is $209.00. The average price target represents 93.70% Increase from the current price of $120.03.
The highest analyst price target is $270.00 ,the lowest forecast is $209.00. The average price target represents 93.70% Increase from the current price of $120.03.
What do analysts say about Palvella Therapeutics?
Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of PVLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.